DBV Technologies DBVT Business Segments — Research and development expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by DBV Technologies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about DBV Technologies's business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is DBV Technologies's business segments — research and development expense?
- DBV Technologies (DBVT) reported business segments — research and development expense of $11.4M in Q1 2026.
- How has DBV Technologies's business segments — research and development expense changed year-over-year?
- DBV Technologies's business segments — research and development expense increased by 7.5% year-over-year, from $10.6M to $11.4M.
- What is the long-term trend for DBV Technologies's business segments — research and development expense?
- Over 2 years (2023 to 2025), DBV Technologies's business segments — research and development expense has grown at a 400.7% compound annual growth rate (CAGR), from $2.06M to $51.59M.
- What does business segments — research and development expense mean?
- Represents the total costs incurred for research and development activities specifically allocated to the Viaskin Peanut product candidate. This includes expenses related to scientific discovery, preclinical testing, and internal research efforts aimed at advancing the therapeutic platform. Monitoring this metric helps investors assess the company's investment intensity in its primary clinical-stage asset.